Evidence map›Paper›PMID 42753054›Full record

ArticleAnnals of surgical oncology2026

Influence of Variant of Uncertain Significance (VUS) Genetic Testing Results on Mastectomy Choice in Lumpectomy-Eligible Patients.

Osvaldo Nunez, Vasanth Govind, Tizita Wolde, Rainya Heath, Tomas Panqueva Baena, Talia R Donenberg, Rachel Silva-Smith, Marie B Jeanjean, Jessica Moore, Samantha A Greenseid and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Osvaldo NunezDepartment of Internal Medicine, University of Miami/Jackson Health Systems, Miami, USA. oxn22@miami.edu.ORCID http://orcid.org/0009-0000-7716-5995
Vasanth GovindDepartment of Psychiatry, University of Miami/Jackson Health Systems, Miami, USA.
Tizita WoldeDewitt Daughtry Department of Surgery, University of Miami, Coral Gables, USA.
Rainya HeathDepartment of General Surgery, Memorial Healthcare System, Hollywood, USA.
Tomas Panqueva BaenaLeonard M. Miller School of Medicine, University of Miami, Coral Gables, USA.
Talia R DonenbergDepartment of Human Genetics, Leonard M. Miller School of Medicine, University of Miami, Coral Gables, USA.
Rachel Silva-SmithDepartment of Human Genetics, Leonard M. Miller School of Medicine, University of Miami, Coral Gables, USA.
Marie B JeanjeanDepartment of Human Genetics, Leonard M. Miller School of Medicine, University of Miami, Coral Gables, USA.
Jessica MooreDepartment of Breast Oncology, Lee Health Cancer Institute, Fort Myers, USA.
Samantha A GreenseidDepartment of Surgery, Emory University, Atlanta, USA.
Jessica CrystalDewitt Daughtry Department of Surgery, University of Miami, Coral Gables, USA.
Susan B KesmodelDewitt Daughtry Department of Surgery, University of Miami, Coral Gables, USA.
Kristin E RojasDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur objective was to evaluate whether having a germline variant of uncertain significance (VUS) influenced the decision to undergo bilateral mastectomy (BLMast) among lumpectomy-eligible patients with unilateral breast cancer.

methodsThis retrospective cohort study included 326 lumpectomy-eligible patients with non-metastatic breast cancer who underwent genetic testing at a single academic center between April 2020 and November 2021. Patients with pathogenic/likely pathogenic variants or contraindications to breast-conserving therapy based on treating surgeon documentation were excluded. The primary outcome was BLMast. Multivariate logistic regression was used to assess the association between VUS results and surgical choice, while adjusting for age, stage, body mass index, family history, and other clinical factors.

resultsAmong the 326 patients who underwent genetic testing and did not carry a pathogenic/likely pathogenic variant, 235 (72.1%) had negative results and 91 (27.9%) had a VUS. A higher proportion of patients with a VUS underwent BLMast than those with negative results (39.7% vs. 24.8%, p = 0.026). On multivariate analysis, patients with VUS were more than twice as likely to undergo BLMast (odds ratio [OR] 2.213; 95% confidence interval [CI] 1.113-4.400; p = 0.023). Other independent predictors included age < 50 years (OR 3.203; 95% CI 1.615-6.354; p < 0.001) and American Joint Committee on Cancer stage III disease (OR 7.065; 95% CI 1.067-46.788; p = 0.043).

conclusionsAmong lumpectomy-eligible patients with unilateral breast cancer, a VUS result on germline genetic testing was independently associated with an increased likelihood of BLMast. These findings should be viewed as hypothesis-generating and underscore the need for improved education and standardized counseling surrounding VUS results to support informed surgical decision-making.

Identifiers

PMID42753054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.